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Abstract
The diagnosis of Creutzfeldt-Jakob disease (CJD) is still
made by exclusion of other dementias. We now evaluat-
ed lactate dehydrogenase (LDH) in the cerebrospinal
fluid (CSF) as a possible additional diagnostic tool. CSF
LDH levels of patients with CJD (n = 26) were compared
with those in other dementias (n = 28). LDH isoenzymes
were determined in a subset (n = 9). Total LDH and isoen-
zyme LDH-1 were significantly higher, whereas the frac-
tions of LDH-2 and LDH-3 were significantly lower in CJD
patients. We conclude that in addition to established CSF
parameters, LDH and its isoenzymes might serve as a
further help to discriminate between CJD and other
dementias.
Copyright © 2004 S. Karger AG, Basel
Introduction
Creutzfeldt-Jakob disease (CJD) is a rare transmissible
disease with rapidly progressive dementia as the leading
symptom. Patients usually die within less than a year after
the onset of symptoms [1, 2]. A definite diagnosis of CJD
can only be made by neuropathological or immunochemi-
cal demonstration of the pathological isoform of the prion
protein (PrPSc) in human brain tissue. Up to now, there
are no reliable diagnostic tests for PrPSc in serum or cere-
brospinal fluid (CSF). The ante-mortem diagnosis is
made according to typical clinical symptoms [3, 4], sup-
ported by typical EEG findings [5], increased concentra-
tions of neuron-specific enolase (NSE) [6, 7], tau protein
[8] protein 14-3-3 [6, 9, 10] and S-100 protein [11] in the
CSF. The latter is also elevated in serum of patients with
CJD [12]. However, these markers only reflect neuronal
destruction. LDH is another accepted marker for cellular
damage. LDH is released by all types of cells after loss of
membrane integrity. CSF-LDH activity is increased in
central nervous system (CNS) infections [13, 14], head
trauma [15, 16], vascular accidents [17], intracerebral
lymphoma [18], organophosphate poisoning [19], and
metastatic CNS disease [20]. However, LDH has not been
investigated, yet in CJD.
Methods
Patients
We investigated CSF samples of 54 patients. All patients with
suspected CJD were initially evaluated clinically [12]. Twenty-six
patients were classified as having CJD by standard clinical criteria [4,
21, 22], the remaining 28 patients suffered from other dementias.
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Fig. 1. a Total CSF activity of LDH in
patients with CJD dementia (n = 26) and
non-CJD dementia (n = 28); CSF LDH of
patients negative for 14-3-3 protein (n = 3)
are marked as dots. b LDH isoenzymes
in patients with CJD dementia and non-
CJD dementia. Median, 25th/75th percen-
tile (box), 5th/95th percentile (whisker cap);
n = 9 in each group.
The male-to-female ratio of patients with CJD was 4/22, their age
was 65.0 B 10.7 years (mean B standard deviation).
Twenty-three of 26 CJD patients were positive for the 14-3-3 pro-
tein in the CSF, in 23 of 26 CJD patients the diagnosis was confirmed
neuropathologically [23]. All three 14-3-3-negative patients were
among the neuropathologically confirmed cases of CJD. All CJD
patients had an intact blood to CSF barrier, reflected by a normal
CSF to serum albumin ratio according to Reiber [24].
Other Dementias
This group comprised 28 patients (11 men, 17 women; age 62.2
B 8.2 years, mean B SD). The final diagnosis in these patients was
made on the basis of the most recent clinical assessment according to
ICD-10 or DSM-IV. The group with other dementias comprised the
following diagnoses: Alzheimer’s disease (n = 12), vascular dementia
(n = 4), dementia due to encephalitis (n = 3), multisystem atrophy
(n = 2), Huntington’s disease (n = 1), paraneoplastic syndrome (n =
1), multiple sclerosis (n = 1), dementia of unknown origin (n = 4).
The study was approved by the local ethics committee in Göt-
tingen.
LDH Measurement
The total LDH activity was measured enzymatically according to
McKenzie and Henderson [25] in all patients. In 9 patients with CJD
and 9 with other dementias CSF LDH isoenzymes were also mea-
sured: CSF had to be concentrated five- to tenfold by ultracentrifuga-
tion (Centrifree-System®, Millipore, Inc., USA). Afterwards, the con-
centrated CSF was mounted onto agarose gel and separated electro-
phoretically. A substrate-specific staining of the different fractions of
LDH was performed by addition of lactate and NAD yielding
NADH which in turn was allowed to react with p -nitroblue tetrazol-
ium chloride (NBT) and phenazine methosulfate. This step results in
oxidation of NADH to NAD and the formation of an NB-formazan
dye which reveals isoenzyme bands. The isoenzyme bands were
quantitated by scanning densitometry at a wavelength of 600 nm.
The test procedure was performed with a commercial electrophoresis
system (LD-Paragon®, Beckman Inc., USA).
Statistical Analysis
As the results of the CJD and non-CJD groups did not follow a
Gaussian distribution, calculations of median (25/75th percentile)
and significances calculated with Mann-Whitney U test are given.
We obtained a cut-off value using the Youden Index [26], though the
limited number of patients does not allow its clinical use.
Results
CSF LDH activity was significantly higher in CJD
patients (mean 9, range 5–13 U/l) than in the non-CJD
group (mean 5, range 4–7 U/l; p = 0.007). The levels of
LDH in 14-3-3-protein-negative CJD patients (n = 3)
ranked among the lowest in the CJD group (fig. 1).
The best cut-off value was 8 U/l, yielding a sensitivity
of 69%, a specificy of 84% (Youden Index 0.53). Isoen-
zymes LDH-1, LDH-2 and LDH-3 could be detected,
fractions of LDH-4 and LDH-5 were usually below the
detection limit.
The percentage of isoenzyme fractions differed signifi-
cantly: LDH-1 was higher in CJD patients (median 92%;
25th/75th percentile 75/96% vs. 57%; 50/61%; p = 0.001),
while both LDH-2 (8%; 4/16% vs. 25%; 21/28%; p =
0.003) and LDH-3 (1%; 0/9% vs. 18%; 15/21%; p =
0.001) were lower as compared with the control group.
Discussion
LDH release in the CSF occurs in various conditions of
acute brain cell damage. Even though CJD has a subacute
clinical course, the results show that the death rate of
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brain cells is still important enough to cause a higher
release of LDH into the CSF than in dementia of other
origins.
Since LDH-1 is the predominant brain LDH isoen-
zyme [20], the increased proportion of this isoenzyme and
the increased total CSF LDH activity reflect the CJD-
induced brain damage well.
Three of the CJD patients were negative for 14-3-3
protein. Their LDH activities were distinctly lower than
the median value of all CJD patients. Hence, the absence
of the scaffolding protein 14-3-3 in CSF might be a sign of
comparatively conserved cellular integrity in 14-3-3-nega-
tive CJD patients.
Our calculated cut-off value doubtless needs to be
interpreted with caution because of the small number of
investigated patients. However, it is already evident that
its differential diagnostic test is as good as that of other
markers, such as 14-3-3, tau protein or S-100B.
We conclude that CSF analysis of total LDH activity
and its subfractions can help in the differential diagnosis
of CJD in a cost-effective manner. Patients lacking 14-3-3
in the CSF might have attenuated brain cell damage as
compared with those CJD patients who are positive for
this protein.
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